The causative agents of acute respiratory infections (ARI) in infants and children are mostly thought to be viruses. Some ARI in adult patients may be caused by bacteria but most often the causes are virus infections. When ARI affect immunocompromised patients or the elderly the mortality rates are significantly higher than in immunocompetent individuals. Many types of viruses cause ARI. Among them, influenza viruses A and B and respiratory syncytial virus (RSV) are thought to be the most important because of the severity of illness after infection and their high communicability in the human population.
Introduction
©1998 International Medical Press 0956-3202/98/$17.00 reported to be 36-78% (Englund et al., 1988; Harrington et al., 1992) . Using data from the annual report of mortality in 1996 in Japan and other countries, the mortality rate with respect to influenza was not high on average throughout all age categories (1.0 per million) and was similar in each country. However, the mortality rate increased three-to 24-fold among the aged (more than 65 years and more than 85 years old, respectively; Matuura et al, 1996) . Similar observations of high mortality rates in the aged were also reported in the USA (Barker, 1986) .
Nosocomial ARI
Although viral ARI is considered to be primarily a disease of children, influenza virus and RSV are now recognized as a cause of serious lower respiratory tract infections in immunocompromised adults and the institutionalized elderly. Nosocomial RSV infections among immunocompromised adults have been reported. Infections have occurred in patients following bone marrow transplantation (Englund et al., 1991; Fouillard et al., 1992; Harrington et al., 1992) , liver transplantation (Pohl et al., 1992) , in those with leukaemia (Englund et al., 1988) and with HIV infection (Chadwani et al., 1990) . The mortality rates of these infected patients were markedly high (Table  1) . Influenza virus also caused high morbidity and mortality among hospitalized elderly patients (Barker, 1986; Falsey et al., 1995) , and PIV-3 was shown to have caused an outbreak of respiratory illness in a paediatric ward (Karron et al., 1993) .
ARI as an emerging disease
Pandemics of influenza have been reported every 10 to 20 years. These pandemics are closely associated with the antigenic shift of influenza A virus from H1N1 to H2N2 and H3N2. The most recent pandemic strains of influenza A virus were H3N2 (Hong Kong type) and the new H1N1 (Russian type). Since the emergence of H3N2 in 1968 and H1N1 in 1977, more than 20 years have passed and a new antigen shift of influenza A virus may occur in the near future. If antigenic shift occurs, the emergence of H2N2 is most probable because 40 years have passed since the last pandemic of Asian flu (H2N2) in 1957. People less than 40 years old lack immunity to H2N2 and a pandemic is expected to occur which particularly affects the younger generation. Influenza B virus also exhibits antigenic drift sequentially every few years and prophylactic treatment of both influenza A and B virus using current vaccines will become ineffective.
Paramyxoviruses are ubiquitous among vertebrates and are occasionally fatal. Seal distemper virus was epizootic among pinnipeds in 1988 (Osterhaus et al., 1988) . Evidence for the emergence of a fatal human infection by an equine morbillivirus has recently been reported (O'Sullivan et al., 1997) .
Viral causative agents of ARI and clinical diagnosis
There are many types of viruses that are causative agents of ARI, including orthomyxoviruses, paramyxoviruses, coronaviruses, picornaviruses, adenoviruses and herpesviruses. Among these, the most important are orthomyxoviruses and paramyxoviruses, which cause acute lower respiratory infections (bronchitis, bronchiolitis and pneumonia). Human ortho-and paramyxoviruses are listed in Table 2 . Stewart-Harris & Schild (1976) described the criteria for clinical diagnosis of ARI and its causative agents. They reported on patients who were clinically diagnosed with influenza but from whom many other viruses apart from influenza virus were isolated. In patients suffering from the 
The discovery and development of antimyxovirus compounds
History of antiviral chemotherapy for ARI Amantadine hydrochloride was the first anti-influenza drug approved for clinical use. However, amantadine was actually first developed as a drug for the treatment of Parkinsonism, before Jackson et al. (1963) reported its efficacy in the prevention of influenza A virus infections during epidemics. Amantadine is only effective against influenza A virus and is not effective against influenza B or C viruses. In addition, amantadine has been known to cause neurological disorders in some patients. In 1979, rimantadine hydrochloride, a derivative of amantadine, was developed. Rimatadine had been used in the USSR and was later reported to be more effective and safer than amantadine in the treatment of influenza (Monto et al., 1995) . Amantadine and rimantadine are absorbed well from the alimentary tract and 100 to 200 mg/day are orally administered to patients. In 1972, ribavirin was developed as an inhibitor of the RNA replication of several viruses. Ribavirin has been approved by the US Food and Drug Administration for use in the treatment of RSV pneumonia and influenza (Knight et al., 1981; Witkowski et al., 1973) . Ribavirin is known to cause haematological disorders when administered by intravenous injection and consequently is administered only by aerosol inhalation (Hall et al., 1983) . In 1995, Glaxo-Wellcome reported that a congener of neuraminic acid, GG167, inhibited the neuraminidase activity of influenza virus. This inhibition is specific to influenza virus neuraminidase. GG167 was reported to be inhibitory against both influenza A and B virus infections in mice, ferrets and humans by intranasal topical administration (DM von Itzstein et al., 1993) . However, GG167 has a very low absorption rate from the gastrointestinal tract and can only be administered to patients using intranasal drops or aerosol inhalation.
Strategies for the screening of antimyxovirus compounds
Influenza virus will infect mice and embryonated chicken eggs. However, only Madin-Darby canine kidney (MDCK) cells show marked CPE caused by influenza virus infection in culture. RSV is cytopathic to HEp2 cells and causes marked syncytium formation. PIV-1, -2 and -3 are infectious to Vero cells but CPE is not apparent. Mumps virus and measles virus cause syncytium formation in Vero cells. To screen for antiviral agents, the most reliable and common methods are the MTT and plaque reduction assays Takeuchi et al., 1991) . However, the CPE caused by myxovirus infection does not have enough of an effect for viable and dead cells to be differentiated in an MTT assay. It is also difficult to induce the formation of plaques of PIV-1, -2, -3 and influenza C virus in tissue culture cells. In addition, counting the plaques of a large number of experimental samples is a laborious process.
We devised several colorimetric methods to determine the antiviral effects of compounds. One of these is based on the haemadsorption of influenza virus, devised by Takeuchi et al. (1993) . Most ortho-and paramyxoviruses (except RSV ) induce the haemadsorption of mammalian and fowl erythrocytes onto the infected cell surface. We determined the peroxidase activity following haemolysis of guinea pig erythrocytes adsorbed to influenza virus-infected MDCK cells using oxidation of o-phenylenediamine in the presence of H 2 O 2 . The colour of the oxidized phenylenediamine was then measured as a marker for influenza virusinfected cells. Another colorimetric assay which quantifies the lactic acid dehydrogenase (LDH) activity of infected cells was devised to detect weakly cytopathogenic myxoviruses including PIV-1, -2 and -3 and influenza C virus (Mori et al., 1995; Watanabe et al., 1995) . LDH leakage from the infected and damaged cells was measured by the amount of coloured formazan formed by the reduction of nitrotetrazolium. The LDH method was found to be more sensitive than the MTT and plaque reduction asssays with respect to virus infectivity titration and the quantification of the antiviral activity of compounds. Leakage of LDH, which is located close to the cell surface membrane, may be measured more easily than the degree of damage to mitochondria, the basis of the MTT method. When most slow-growing myxoviruses, for example PIV-1 and influenza C virus, were titrated with HMV-2 cells (derived from a human melanoma), the increase in MTT-reducing activity and the decrease in the activity of leaked LDH were calculated to be parallel according to the degree of dilution of the inoculated virus ( Fig. 1 ).
Replication of ortho-and paramyxoviruses and inhibitors of replication
The growth cycle of myxoviruses in mammalian cells is known to involve five major steps. They are: (i) attachment and penetration; (ii) uncoating; (iii) replication of vRNA and transcription of mRNA; (iv) translation of mRNA to polypeptides and assembly of particles; (v) release of particles from cells. Research to identify inhibitors for each step of this cycle is currently underway.
Inhibitors of attachment and penetration
Dextran sulphate and sulphated polysaccharides. The surface of the cell membrane is normally negatively charged. Virus particles (virions) are attracted to the cell membrane electrostatically and then bind to a specific receptor via the HA, HN or G proteins of virions. Sulphated polysaccharides, which are negatively charged, are thought to disturb the approach and binding of the virions to receptors non-specifically. Dextran sulphate is a well known inhibitor of HIV replication and inhibits the binding of virions to the CD4 receptor . Dextran sulphate also inhibits the replication of RSV and influenza A virus but not the replication of influenza B virus, measles virus or PIV-3 (Hosoya et al., 1991) . A natural sulphated polysaccharide OKU-40 was extracted from the marine microalgae Dinoflagellata and was found to inhibit the replication of HIV, RSV, influenza A and B viruses, measles virus and PIV-2. However, it did not inhibit the replication of mumps virus or PIV-3 (Hasui et al., 1995) . Thus, the action of negatively charged polysaccharides is not merely one of non-specific inhibition of the binding of an enveloped virus to receptors. OKU-40 did not inhibit the binding of HIV or influenza A virus to the cell membrane but did inhibit the fusion of the membranes of HIV-infected MOLT-4 cells to those of uninfected cells and the fusion of the influenza A virus envelope to uninfected MDCK cells (Hashimoto et al., 1996) .
PM-523. Polyoxometalates, which are clusters of polyoxonic acid molecules, are composed of transition metal ions (W, Mn, Nb, V etc.) and six oxygen atoms, and are negatively charged. There are many types of polyoxometalates, which are differentiated by their cluster shape and type of nucleic metal ions. Polyoxometalates inhibit oxidation and reduction reactions in vitro and inhibit the replication of HIV, herpes simplex virus (HSV) and influenza virus in tissue culture cells. The antiviral activity of a polyoxometalate against influenza virus and RSV was reported to be highly dependent on its type of cluster and nuclear metal ions Huffman et al., 1997) . We investigated the inhibitory effects of 86 polyoxometalates on ortho-and paramyxoviruses in a tissue culture system and among these, PM-523, a titanium-centred Keggin-type polyoxotungstate, emerged as the most potent and selective antimyxovirus compound . PM-523 inhibited replication of influenza A virus, RSV and PIV-2 at concentrations of 2 to 3 µM and inhibited mumps virus and influenza B virus at concentrations of 10 to 40 µM. At a concentration of 400 µM PM-523 was not toxic to MDCK cells. PM-523 and ribavirin were combined at a ratio of 1 : 16 and a 50% inhibitory dose (EC 50 ) and EC 70 against influenza A virus replication in MDCK cells was determined. The EC 50 and EC 70 of the combination were found to be consistently lower than those for each compound used alone. The combination index was calculated by the formula of Chou (1987) and was less than 0.6. This indicates the combined effect of the compounds was synergistic (Shigeta et al., 1997) . PM-523 was investigated for anti-influenza A virus activity in vivo by the aerosol exposure of mice, which had been infected by the intranasal route with a lethal dose of the virus (H1N1, PR8). Fifty percent of the infected mice survived to the 9th day post-infection following exposure to 4.8 mM PM-523 for 2 h twice daily for 4 days, whereas all infected and untreated mice died. When we combined PM-523 and ribavirin at a ratio of 1 : 16 and then treated the infected mice, a synergistic and improved therapeutic effect was achieved compared with the individual use of both compounds; 80% of mice survived to the 9th day (Shigeta et al., 1997; Fig. 2) . The virus titre in the lungs of the untreated infected mice increased to 10 6 p.f.u./g after 48 h of infection. In contrast, the virus titres in the lungs of the infected mice that were treated with the combination of PM-523 and ribavirin were consistently lower than those in the lungs of untreated mice or those treated with the compounds individually.
Mechanism of anti-influenza virus action of PM-523.
In order to analyse the antiviral activity of PM-523, we performed a time of addition study of this inhibitor against influenza virus-and RSV-infected cells. When the compound was added to the tissue culture system throughout the course of infection, it inhibited both influenza virus and RSV replication. When the compound was added 1 h before to 1.5 h after infection, during which the adsorption of virus to cells occurs, it was found to inhibit RSV replication but not that of influenza virus. When the compound was added after adsorption of the virus to the end of infection, it was found to inhibit both RSV and influenza virus replication.
We at first believed that PM-523 inhibited binding of the virus to the cell membrane because it is a negatively charged inorganic compound. However, when we examined the surface of the MDCK cells that had been incubated with influenza virus and subjected to immunofluorescent staining using anti-influenza virus antibody and FACScan analysis, we found that PM-523 did not inhibit the binding of the virus to the cell membrane even at the highest concentration tested (200 µM; Shigeta et al., 1996) . Next, we investigated the fusion of the influenza virus envelope to the cell membrane using a fluorescence dequenching method (Hoekstra et al., 1984) . As shown in Fig. 3 , when the influenza virus envelope was labelled with fluorescent rhodamine and the density of rhodamine molecules was very high, the fluorescence was quenched and could not be detected by the sensor. When fusion of the envelope and the cell membrane occurred, the fluorescent molecules were dispersed throughout the membrane layer and the fluorescence was dequenched and was detected by the sensor. We investigated the effects of PM-523 on fusion using this fluorescence dequenching method. The addition of PM-523 to a mixture of rhodamine-labelled influenza virus and MDCK cells inhibited recovery of the fluorescence, which confirmed that PM-523 inhibited fusion of the influenza A virus envelope to the cell membrane. In contrast, when influenza B virus, Sendai virus (parainfluenzavirus of the mouse) or Newcastle disease virus (rubulavirus of chicken; Table 2 ) were used instead of influenza A virus for the fusion assay, PM-523 did not inhibit fusion. This result indicated that the PM-523 inhibition of fusion is specific for influenza A virus.
BMY-27709. After the adsorption of influenza virus particles to the cell membrane, they are engulfed in phagosomes. The HA of the infectious virus has been cleaved to HA1 and HA2 by cellular protease when it was released from the infected cell. The cleavage of HA results in a conformational change in the HA molecule at the low pH of the endosome and the edge of the cleaved HA2 approaches the cell membrane. A hydrophobic amino acid group at the edge of HA2 nicks the cell membrane, and the viral envelope membrane and the cell membrane are able to fuse. This process of penetration of target cells by influenza virus is unique (Fig. 4) Fusion and penetration O be inhibitory against influenza A virus H1N1 and H2N2 but not inhibitory against H3N2 or influenza B virus. Virus strains resistant to BMY-27709 were isolated by passage of influenza A virus in the presence of BMY-27709. The resistant strains showed several point mutations in their HA genes. Among them, two major amino acids changes were found, at positions Met-313 of HA1 and Phe-110 of HA2, both of which are located near the fusion peptide. A monoclonal antibody specific for the low pH form of HA was used to detect the conformational change in HA. BMY-27709 inhibited the appearance of this antigen in the HA of the wild-type strain but did not in the HA of the resistant strain. Thus, BMY-27709 was shown to bind to cleaved HA and inhibit its low pH-induced conformational change in (Luo et al., , 1997 .
Neutralizing antibody to RSV. Human intravenous immunoglobulin (IgIV) containing a neutralizing antibody to RSV was used for the prophylaxis of severe RSV infection in a multicentre trial programme. IgIV was safe to use and in many cases prevented RSV infections but its efficacy was dependent on the neutralizing antibody titre (Groothuis, 1994; Meissner et al., 1993) . Murine monoclonal antibody to RSV F glycopotein was reported to inhibit experimental RSV infection of rhesus monkeys (Weltzin et al., 1996) . Antibodies to RSV G or F glycoprotein neutralize the infectivity or inhibit the fusion activity of viruses, thus inhibiting the adsorption penetration of cells. Pretreatment of cotton rats with a human monoclonal antibody to RSV F protein (MEDI-493) was reported to inhibit infection with RSV and to result in a 99% reduction of lung RSV titre at a dose of 2.5 mg/kg ( Johanson et al., 1997) . Virus particles adsorb to the cell membrane via HA. HA is cleaved by protease to HA1 and HA2. After a conformational change in cleaved HA, a fusion peptide of HA2 approaches the cell membrane and mediates the fusion of the virus envelope membrane and cell membrane. M2 opens the ion channel of the viral envelope at low pH in endosomes. The influx of protons causes dissociation of the M1 protein and the nucleocapsid and viral genomes enter the cytoplasm.
Synthetic ICAM-1 as a receptor for rhinoviruses.
Intercellular adhesion molecule 1 (ICAM-1) has been identified as the cellular receptor for the major serogroups of human rhinoviruses. Recombinant soluble forms of ICAM-1 (sICAM-1) showed anti-rhinovirus activity in vitro, which was mediated by competition for the receptor binding sites on the viruses. Ohlin et al. (1994) of Miles Biotechnology investigated the antiviral activity of sICAM-1 against 52 reference strains and 34 clinical isolates of rhinoviruses. sICAM-1 was found to inhibit the replication of all major groups of rhinoviruses but not of minor serotypes (2, 25, 44 and 62). IC 50 (50% inhibitory concentration) values of sICAM-1 were similar between the reference viruses and clinical isolates. Two domains of ICAM-1 molecules are chemically coupled with the heavy chain of IgA. These chimeric molecules (IC1-5D/IgA) exhibited 60-to 170-fold higher anti-rhinovirus activity than sICAM-1 against the major serogroups of rhinoviruses (Crump et al., 1994) . IC1-5D/IgA not only inhibited the adsorption of virus to the receptor but also neutralized the infectivity of viruses.
Inhibitors of uncoating
Amantadine and rimantadine. Amantadine inhibits the replication of influenza A virus but does not inhibit that of influenza B virus (Fig. 5a ). During a course of chemotherapy for the treatment of influenza virus infection using amantadine, a virus resistant to amantadine was isolated (Belshe et al., 1989) . This discovery shed light on the unique mechanism of the anti-influenza virus activity of amantadine and also on the function of the matrix protein (M2) of the virus. M2 protein is present on the viral envelope of influenza virus as well as on the membrane of infected cells and forms a tetramer. The protein is encoded by the virus genome RNA segment 7 and the peptide has 96 amino acids. From the N terminus of the peptide, 23 amino acids are found outside the cell membrane, 19 in the transmembrane region and 54 inside the membrane. The resistant virus was found to have mutations of Val-27 or Leu-3, which are present in the transmembrane region of the peptide. This region is located at the position of ion channels in the membrane. By transfection of oocytes of Xenopus laevis with the M2 gene, M2 protein was synthesized in the oocyte membrane. This membrane acted as an ion channel and the activity of the channel was determined by measuring the electric current through the membrane. As a result of this investigation, it was shown that 1 molecule of amantadine inhibited 1 unit of channel activity (Wang et al., 1993) . The mechanism of inhibition of virus growth by amantadine is explained as follows.
Owing to the inhibition of the ion channel activity of the envelope of influenza virus, protons are unable to enter the virions and dissociation of the M1 protein (another matrix protein) and the nucleocapsid does not occur (inhibition of uncoating). A spirene containing imidazoline (BL-1743) was recently isolated from yeast cells and reported to show a similar M2 ion channel inhibitory activity to amantadine (Tu et al., 1996) . The clinical efficacy of the prophylaxis and treatment of influenza virus infections with amantadine and rimantadine is discussed in a review by Hayden (1997) . Protease inhibitors. As described above, influenza virus HA needs to be cleaved into HA1 and HA2 before penetration of the virus into cells. The F protein of paramyxoviruses is also cleaved to F1 and F2 prior to the fusion of the envelope and the cell membrane. The protease that cleaves HA or F is not viral in origin but is a host cellular protease. Proteases that cleave the HA or F of myxoviruses were isolated from chick embryos and rat bronchiolar cells (Gotoh et al., 1990; Kido et al., 1993) . Thus, inhibition of virus replication by inhibition of protease activity appears not to be virus-specific; several protease inhibitors have been shown to inhibit the growth of influenza virus in MDCK cells. Camostat mesylate (foipan) and nafamostat mesylate (futhan) are commercial drugs for the treatment of acute pancreatitis and protect intact tissues from the proteolytic process of acute pancreatitis. Hosoya et al. (1992 Hosoya et al. ( , 1993 reported that these protease inhibitors inhibited the cleavage of HA and were highly inhibitory against influenza A and B virus replication in both MDCK cells and embryonated chicken eggs.
Fusion protein mimics. Paramyxoviruses and HIV share a common feature: fusion between infected and uninfected cells. HIV gp41 exists in the transmembrane of the envelope and is associated with the fusion activity of the virus. In gp41, two polypeptides (35 to 37 amino acids each), designated dp107 and dp178, have coiled structures. Synthetic peptides with amino acid sequences identical to those of dp107 or dp178 were found to inhibit the fusion activity of HIV ( Jiang et al., 1993; Wild et al., 1993) . Lambert et al. (1996) investigated paramyxovirus envelopes to identify a peptide with amino acid sequences and secondary coiled structures similar to those of dp107 or dp178 using a computer software package. They found similar structures in the HR2 domain of F1 glycoproteins of RSV, PIV-3 and measles virus. The synthetic proteins of RSV F1 474-523, PIV F1 438-493 and measles virus F1 438-488 inhibited syncytium formation in cells infected by the respective viruses. The inhibitory activity of each peptide was virusspecific. Both the HIV transmembrane protein (gp160) and the paramyxovirus F0 protein share a common feature, both being glycosylated in endosomes and cleaved into two molecules at the surface of cell membranes by cellular proteases. gp160 is cleaved to gp120 and gp41 and F0 is cleaved to F1 and F2. Following cleavage of the proteins, HR2 in paramyxovirus F1 (corresponding to dpP178 in HIV gp41) is thought to approach the fusion protein (hydrophobic peptide at the edge of the F1 cleavage site) and mediate its fusion activity. The synthetic peptide of HR2 may interfere with the binding of HR2 and the fusion peptide and further inhibit the fusion of the viral envelope membrane and the cell membrane. Similar synthetic oligopeptides consisting of 6 to 10 amino acids were synthesized based on the sequence of the G protein of RSV and were reported to inhibit RSV replication (C Ryan et al., 1995) . In contrast, a region which includes 83 amino acids in the extracellular domain of the HN protein of PIV is reported to be essential for the fusion activity of F1 (Tanabayashi & Compans, 1996) . A monoclonal antibody against this domain was reported to inhibit fusion between PIV-2-infected and uninfected cells (Yuasa et al., 1995) .
WIN series of uncoating inhibitors. The Sterling-
Winthrop Research Institute reported on uncoating inhibitors of rhinoviruses. These compounds were rationally designed to enter and bind to pockets on the virion capsid of rhinoviruses. As a result of the binding of these compounds in the pocket, the rhinovirus virion loses its flexibility and is unable to uncoat the capsid (Kim et al., 1993) . Among several numbered WIN compounds, VP63843 (pleconaril) was most recently developed. Pleconaril was a modification of another WIN compound with antiviral activity, WIN61893. It was reported to have improved metabolic stability and demonstrate a wider range of anti-rhinovirus activity when compared to WIN61893 (Diana et al., 1995) . Pleconaril was evaluated against upper respiratory infection with coxsackie virus A21 and was found to be effective when administered orally (200 mg three times per day) prior to infection (Schiff GM, McKinlay MA & Sherwood JR; Oral efficacy of VP63843 in coxsackievirus A21-infected volunteers; Interscience Conference on Antiviral agents and Chemotherapy, 16-19 September, 1996 ; Abstract H43). The current status of investigations into anti-picornavirus drugs was reviewed by Diana & Pevear (1997) .
Inhibitors of RNA replication and transcription
Orthomyxoviruses have 7-8 segments of genomic RNA. Segments 1-3 encode components of the RNA-dependent RNA polymerase complex, PA, PB1 and PB2. Paramyxovirus RNA polymerase is coded by a single gene, L. The nucleotide sequences of the three segments of genomic RNA of orthomyxoviruses and the L gene of paramyxoviruses are evolutionarily well conserved, regardless of the type and subtype of influenza virus or the genus and subfamily of paramyxovirus (rubulavirus, paramyxovirus, morbillivirus) (Lamb & Krug, 1996; Pringle & Easton, 1997) . Thus, the RNA polymerases of ortho-and paramyxoviruses may be targets for inhibitors within each virus family.
Antisense oligonucleotides targeted to the viral genome. Antisense oligonucleotides targeted against RSV or influenza A virus genomic RNA were reported to inhibit virus replication. RSV NS2 and influenza virus PB2 genomes were selected as the target sites and the antisense oligonucleotides were found to inhibit virus replication, antigen appearance and mRNA transcription of these regions of the genome of both viruses (Hatta et al., 1997; Jairath et al., 1997) . Several factors have been shown to be important in the design of effective antisense oligonucleotides, including the target being an intragenic sequence (Hatta et al., 1997; Jairath et al., 1997) , and the oligonucleotide being encapsulated with liposomes (Hatta et al., 1997) or linked with 2′,5′-oligoadenylates (Cirino et al., 1997) .
Inhibitors of capping of mRNA. For the transcription of mRNA from the genomic RNA of negative strand RNA viruses, capping of mRNA as a primer of transcription is necessary. In the nucleosides that comprise the cap, a methylated guanine at position 7 has to be present. It has been reported that S-adenosylmethionine to S-adenosylhomocysteine (S-AH) cycles of the host cell-metabolism are utilized to methylate guanine residues in the caps of paramyxovirus mRNA. When the activity of S-AH hydrolase is inhibited, S-AH accumulates and sequentially inhibits transmethylation of the cap guanine of mRNA.
Neplanocin A, a carbocyclic adenosine, is a potent inhibitor of S-AH hydrolase, but is known to be cytotoxic. Workers at Asahi Chemical Company synthesized a noncytotoxic congener of neplanocin A designated TJ13025 (Fig. 5b) . We investigated TJ13025 and ribavirin for their inhibitory activities against paramyxoviruses and orthomyxoviruses. TJ13025 was found to be inhibitory against PIV-1 and -2, mumps virus and measles virus at lower concentrations than ribavirin (Table 3 ). In contrast, it did not inhibit influenza virus or RSV . Thus, we confirmed that influenza virus does not use the host S-AH cycle to methylate the guanine of the mRNA cap. On the other hand, the majority of paramyxoviruses, excluding RSV, use the S-AH cycle for this purpose and therefore the S-AH hydrolase inhibitor is a very potent inhibitor of paramyxoviruses. It is unclear why TJ13025 did not inhibit RSV replication, but is likely that RSV utilizes an unknown pathway to methylate the guanine of the mRNA cap. Another inhibitor of the capping of viral mRNA is a dioxobutanoic acid designated L-735882 ( Fig. 5b) , which inhibits the endonuclease activity of influenza virus. Influenza virus possesses a unique system for the cap formation of mRNA, utilizing the cap of host cell mRNA as primer for its own mRNA transcription. PB2, which possesses this endonuclease activity, removes the caps of host cell mRNA molecules and connects them to the 5′end of the viral mRNA (Fig. 6 ). L-735882 inhibits this endonuclease activity and subsequently inhibits the replication of influenza virus in cells (Cianci et al., 1996; Tomassini et al., 1994) .
Inhibitors of virus RNA replication.
Ribavirin is an analogue of guanosine and is well known as an antiviral compound for several RNA viruses. The mechanism of action of ribavirin is non-specific; it inhibits inosine monophosphate (IMP) dehydrogenase activity in cells and also decreases the amount of xanthosine monophosphate and guanosine monophosphate in infected cells, thus inhibiting viral RNA synthesis (Gilbert & Knight, 1986) . Mizoribine, an inhibitor of RNA synthesis, has been used as an immunosuppressor administered after organ transplants. Mizoribine is a potent inhibitor of IMP dehydrogenase, as is ribavirin (Fig. 7a) . We investigated the antiviral activity of mizoribine against several ortho-and paramyxoviruses and found that it possesses potent antiviral activity (Kosugi et al., 1994) .
Recently, 2′-deoxy-2′-fluoroguanosine (2′-fluoroguo) was synthesized as an anti-influenza virus RNA polymerase inhibitor (Fig. 7a ). 2′-Fluoroguo was reported to be phosphorylated by cellular kinase, and 2′-fluoroguo triphosphate was found to inhibit specifically influenza virus RNA polymerase activity ( Jakeman et al., 1994; Tisdale et al., 1995) .
Inhibitors of virus release from cells
In 1995, a group from Glaxo-Wellcome reported on the influenza virus neuraminidase inhibitor GG167 (Fig. 7b ). GG167 inhibited influenza virus neuraminidase activity but did not inhibit this activity in paramyxoviruses, bacteria or mammalian cells. GG167 was absorbed to a very low Hayden et al., 1997a) . Data from double-blind field trials with zanamivir carried out during the 1994-1995 influenza season demonstrated that the mean duration of symptoms was reduced from approximately 5-6 days in the placebo group to 3-4 days in treated patients. The alleviation of major symptoms occurred at least 3 days faster in the treated group compared to the placebo group (Hayden et al., 1997b) . Zanamivir was also reported to be efficacious in reducing otologic manifestations of experimental human influenza virus infection (Walker et al., 1997) . No concerns were expressed regarding the adverse effects of the drug. Drug-resistant viruses were isolated by passaging influenza virus in MDCK cells growing in culture medium containing zanamivir, but the potential for development of a resistant virus strain during zanamivir therapy appears to be lower than that seen with amantadine.
More recently, a group from Gilead Science developed a carbocyclic transition state analogue of sialic acid, designated GS4104 (Fig. 7b ). Oral administration of GS4104 in dogs resulted in good bioavailability of 30 to 100%. In rats after absorption from the alimentary tract, GS4104 changes to its non-ester form, GS4071, and is distributed efficiently to the lungs (Eisenberg et al., 1997) . The efficacy of orally administered GS4104 was measured by the survival of influenza virus-infected mice through treatment with 10 mg/kg/day for 5 days (Hitchcock, 1996) .
Conclusion and the future
Progress in virology has made it possible to develop compounds that inhibit viral replication in cells. Clinical application of such inhibitors in the treatment of viral infections has been successful in herpesvirus infections (Elion et al., 1977; Tyring et al., 1995) and HIV infections (Mellows, 1996; Mitsuya et al., 1985; Robert et al., 1990) . The prophylactic use of amantadine and rimantadine for influenza A virus infections and therapeutic aerosol inhalation of ribavirin for patients with severe RSV infections have been recommended. However, there is a continuing need for more effective antiviral agents to manage viral ARI. The only vaccine for the causative viruses of ARI is an inactivated influenza virus vaccine and its use is mainly focused on the prevention of severe disease in immunocompromised hosts and in the aged. The efficacy of the vaccine in preventing influenza among the young has not been fully investigated (Coach & Cate, 1983) . Inactivated vaccines against RSV and PIV have been previously tested in infants but testing was discontinued owing to the severe adverse effects that occurred when immunized infants were exposed to the native viruses (Chin et al., 1969) . Recently, several effective compounds against the causative agents of ARI have been discovered and are being developed (Table 4 and 5).
Epidemics of ARI have a worldwide economic, as well as social, impact. In order to minimize the mortality rates in compromised hosts and the elderly during epidemics of ARI, the development of more potent and safe antiviral drugs for ARI is urgently needed. What remains to be done in the future is to find drugs with more broad spectrum efficacy for myxoviruses, picornaviruses and adenoviruses. Also needed are more rapid and simple diagnostic methods for detecting the various causative viruses of ARI.
Note added in proof
In May 1997, a 3 year old boy in Hong Kong died of respiratory disturbance after an influenza-like disease. Before his death an influenza A virus strain of the H5N1 subtype was isolated from a sample of his bronchial aspirate. Between November 1997 and January 1998, 18 cases of the H5N1 virus were reported, and 6 patients died. Most of the fatalities were causes by pneumonia or multiple organ failure syndrome. The influenza A virus H5N1 strain was isolated from chickens in several Hong Kong markets but not from other birds including ducks, pigeons and flamingos. After extensive surveillance of HA antibody in the Hong Kong population, it was found that the incidence of infection with the H5N1 strain was very low. Among the people with H5N1 antibody, only a few had any evidence of contact with patients with H5N1 infection and direct person-to-person spread of the subtype is therefore considered to be negative. As of February 1998, there have been no reports of influenza A virus H5N1 infection in any other countries.
